Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ETV6 - NTRK2 |
Gene Variant Detail | |
Relevant Treatment Approaches | Trk Receptor Inhibitor (Pan) Larotrectinib |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ETV6 - NTRK2 | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture (PMID: 26939704). | 26939704 |
ETV6 - NTRK2 | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591). | 26884591 |
ETV6 - NTRK2 | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ETV6-NTRK2 in culture (PMID: 30093503). | 30093503 |
ETV6 - NTRK2 | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | DS6051b | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568). | 31399568 |
ETV6 - NTRK2 | acute myeloid leukemia | sensitive | Larotrectinib Trk Receptor Inhibitor (Pan) | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical study, a patient with secondary AML achieved a partial remission when treated with Vitrakvi (larotrectinib), showing complete elimination of the cell population harboring ETV6-NTRK2, and the patient-derived xenograft (PDX) model harboring ETV6-NTRK2 showed sensitivity to treatment with Vitrakvi (larotrectinib), demonstrating a decrease in ETV6-NTRK2-expressing cells (PMID: 29920189). | 29920189 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|